A Focus on the Preclinical Development and Clinical Status of the Histone Deacetylase Inhibitor, Romidepsin (Depsipeptide, Istodax^®)

• Nakajima H , KimYB, TeranoH, YoshidaM, HorinouchiS. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res.241(1) , 126–133 (1998).
   PubMed Web of Science ®Google Scholar
• Whittaker SJ , DemierreMF, KimEJet al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28(29) , 4485–4491 (2010).
   PubMed Web of Science ®Google Scholar
• Piekarz RL , FryeR, TurnerMet al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27(32) , 5410–5417 (2009).
   PubMed Web of Science ®Google Scholar
• Jones PA , BaylinSB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet.3(6) , 415–428 (2002).
   PubMed Web of Science ®Google Scholar
• Kuendgen A , StruppC, AivadoMet al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104(5) , 1266–1269 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G , KantarjianHM, Sanchez-GonzalezBet al. Phase 1/2 study of the combination of 5-aza-2´-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10) , 3271–3279 (2006).
   PubMed Web of Science ®Google Scholar
• Gore SD , WengLJ, ZhaiSet al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 7(8) , 2330–2339 (2001).
   PubMed Web of Science ®Google Scholar
• Gore SD , BaylinS, SugarEet al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66(12) , 6361–6369 (2006).
   PubMed Web of Science ®Google Scholar
• Bishton M , KenealyM, JohnstoneR, RasheedW, HM Prince. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Rev. Anticancer Ther.7(10) , 1439–1449 (2007).
   PubMed Web of Science ®Google Scholar
• Prince HM , BishtonMJ, HarrisonSJ. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res15(12) , 3958–3969 (2009).
   PubMed Web of Science ®Google Scholar
• Thiagalingam S , ChengKH, LeeHJ, MinevaN, ThiagalingamA, PonteJF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci.983 , 84–100 (2003).
   PubMed Web of Science ®Google Scholar
• Kim JY , CasacciaP. HDAC1 in axonal degeneration: a matter of subcellular localization. Cell Cycle9(18) , 3680–3684 (2010).
   PubMed Web of Science ®Google Scholar
• Kim JY , ShenS, DietzKet al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat. Neurosci. 13(2) , 180–189 (2010).
   PubMed Web of Science ®Google Scholar
• Sakai H , UranoT, OokataKet al. MBD3 and HDAC1, two components of the NuRD complex, are localized at aurora-A-positive centrosomes in M phase. J. Biol. Chem. 277(50) , 48714–48723 (2002).
   PubMed Web of Science ®Google Scholar
• Frye RA . Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun.260(1) , 273–279 (1999).
   PubMed Web of Science ®Google Scholar
• Bhalla KN . Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol.23(17) , 3971–3993 (2005).
   PubMed Web of Science ®Google Scholar
• Bolden JE , PeartMJ, JohnstoneRW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5(9) , 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Dokmanovic M , MarksPA. Prospects: histone deacetylase inhibitors. J. Cell. Biochem.96(2) , 293–304 (2005).
   PubMed Web of Science ®Google Scholar
• Ueda H , NakajimaH, HoriYet al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo) 47(3) , 301–310 (1994).
   PubMed Web of Science ®Google Scholar
• Ueda H , NakajimaH, HoriY, GotoT, OkuharaM. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem.58(9) , 1579–1583 (1994).
   PubMed Web of Science ®Google Scholar
• Lee JS , PaullK, AlvarezMet al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46(4) , 627–638 (1994).
   PubMed Web of Science ®Google Scholar
• Sandor V , BakkeS, RobeyRWet al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8(3) , 718–728 (2002).
   PubMed Web of Science ®Google Scholar
• Isodax®, package insert. Celgene Corporation, NJ, USA.
   Google Scholar
• Berg SL , StoneJ, XiaoJJet al. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother. Pharmacol. 54(1) , 85–88 (2004).
   PubMed Web of Science ®Google Scholar
• Furumai R , MatsuyamaA, KobashiNet al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62(17) , 4916–4921 (2002).
   PubMed Web of Science ®Google Scholar
• Bradner JE , WestN, GrachanMLet al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6(3) , 238–243 (2010).
   PubMed Web of Science ®Google Scholar
• Ruefli AA , AusserlechnerMJ, BernhardDet al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA 98(19) , 10833–10838 (2001).
   PubMed Web of Science ®Google Scholar
• Rosato RR , AlmenaraJA, MaggioSCet al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol. Cancer Ther. 7(10) , 3285–3297 (2008).
   PubMed Web of Science ®Google Scholar
• Subramanian C , OpipariAW Jr, Bian X, Castle VP, Kwok RP. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA102(13) , 4842–4847 (2005).
   PubMed Web of Science ®Google Scholar
• Rosato RR , KollaSS, HockSKet al. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J. Biol. Chem. 285(13) , 10064–10077 (2010).
   PubMed Web of Science ®Google Scholar
• Yi C , MaM, RanLet al. Function and molecular mechanism of acetylation in autophagy regulation. Science 336(6080) , 474–477 (2012).
   PubMed Web of Science ®Google Scholar
• Robert T , VanoliF, ChioloIet al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471(7336) , 74–79 (2011).
   PubMed Web of Science ®Google Scholar
• Vrana JA , DeckerRH, JohnsonCRet al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-xL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18(50) , 7016–7025 (1999).
   PubMed Web of Science ®Google Scholar
• Richon VM , SandhoffTW, RifkindRA, MarksPA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA97(18) , 10014–10019 (2000).
   PubMed Web of Science ®Google Scholar
• Waby JS , ChirakkalH, YuCet al. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol. Cancer 9 , 275 (2010).
   PubMed Web of Science ®Google Scholar
• Brazelle W , KreahlingJM, GemmerJet al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS ONE 5(12) , e14335 (2010).
   PubMed Web of Science ®Google Scholar
• Noh EJ , LimDS, JeongG, LeeJS. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem. Biophys. Res. Commun.378(3) , 326–331 (2009).
   PubMed Web of Science ®Google Scholar
• Stevens FE , BeamishH, WarrenerR, GabrielliB. Histone deacetylase inhibitors induce mitotic slippage. Oncogene27(10) , 1345–1354 (2008).
   PubMed Web of Science ®Google Scholar
• Warrener R , BeamishH, BurgessAet al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17(11) , 1550–1552 (2003).
   PubMed Web of Science ®Google Scholar
• Robbins AR , JablonskiSA, YenTJet al. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 4(5) , 717–726 (2005).
   PubMed Web of Science ®Google Scholar
• Harrison SJ , QuachH, LinkEet al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 118(24) , 6274–6283 (2011).
   PubMed Web of Science ®Google Scholar
• Mitsiades N , MitsiadesCS, RichardsonPGet al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101(10) , 4055–4062 (2003).
   PubMed Web of Science ®Google Scholar
• Duan H , HeckmanCA, BoxerLM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell. Biol.25(5) , 1608–1619 (2005).
   PubMed Web of Science ®Google Scholar
• Witzig TE , TimmM, StensonM, SvingenPA, KaufmannSH. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin. Cancer Res.6(2) , 681–692 (2000).
   PubMed Web of Science ®Google Scholar
• Dhordain P , LinRJ, QuiefSet al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 26(20) , 4645–4651 (1998).
   PubMed Web of Science ®Google Scholar
• Pasqualucci L , BereschenkoO, NiuHet al. Molecular pathogenesis of non-Hodgkin‘s lymphoma: the role of Bcl-6. Leuk. Lymphoma 44(Suppl. 3) , S5–S12 (2003).
   PubMed Web of Science ®Google Scholar
• Kawamata N , KoefflerHP. Mantle cell lymphoma: SAHA blocks Akt/mTOR pathway and reduces cyclin D1 protein levels by affecting translation. ASH Annual Meeting Abstracts104(11) , 3293 (2004).
   Google Scholar
• Catley L , WeisbergE, Tai Y-T et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood102(7) , 2615–2622 (2003).
   PubMed Web of Science ®Google Scholar
• Peart MJ , SmythGK, Van Laar RK et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA102(10) , 3697–3702 (2005).
   PubMed Web of Science ®Google Scholar
• Mitsiades CS , MitsiadesNS, McMullanCJet al. Transcriptional sig nature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl Acad. Sci. USA 101(2) , 540–545 (2004).
   PubMed Web of Science ®Google Scholar
• Nebbioso A , ClarkeN, VoltzEet al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11(1) , 77–84 (2005).
   PubMed Web of Science ®Google Scholar
• Maeda T , TowatariM, KosugiH, SaitoH. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood96(12) , 3847–3856 (2000).
   PubMed Web of Science ®Google Scholar
• Magner WJ , KazimAL, StewartCet al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165(12) , 7017–7024 (2000).
   PubMed Web of Science ®Google Scholar
• Inoue S , MacfarlaneM, HarperN, WheatLM, DyerMJ, CohenGM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ.11(Suppl. 2) , S193–S206 (2004).
   PubMed Web of Science ®Google Scholar
• Aron JL , ParthunMR, MarcucciGet al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102(2) , 652–658 (2003).
   PubMed Web of Science ®Google Scholar
• Dai Y , ChenS, KramerLB, FunkVL, DentP, GrantS. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin. Cancer Res.14(2) , 549–558 (2008).
   PubMed Web of Science ®Google Scholar
• Khan SB , MaududiT, BartonK, AyersJ, AlkanS. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br. J. Haematol.125(2) , 156–161 (2004).
   PubMed Web of Science ®Google Scholar
• Piekarz RL , RobeyRW, ZhanZet al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103(12) , 4636–4643 (2004).
   PubMed Web of Science ®Google Scholar
• Robey RW , ZhanZ, PiekarzRL, KayasthaGL, FojoT, BatesSE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin. Cancer Res.12(5) , 1547–1555 (2006).
   PubMed Web of Science ®Google Scholar
• Peart MJ , TaintonKM, RuefliAAet al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63(15) , 4460–4471 (2003).
   PubMed Web of Science ®Google Scholar
• Choudhary C , KumarC, GnadFet al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942) , 834–840 (2009).
   PubMed Web of Science ®Google Scholar
• Terui T , MurakamiK, TakimotoRet al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res. 63(24) , 8948–8954 (2003).
   PubMed Web of Science ®Google Scholar
• Subramanian C , JarzembowskiJA, OpipariAW Jr, Castle VP, Kwok RP. HDAC6 deacetylates Ku70 and regulates Ku70–Bax binding in neuroblastoma. Neoplasia13(8) , 726–734 (2011).
   PubMed Web of Science ®Google Scholar
• Bishton MJ , HarrisonSJ, MartinBPet al. Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 117(13) , 3658–3668 (2011).
   PubMed Web of Science ®Google Scholar
• Yu X , GuoZS, MarcuMGet al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94(7) , 504–513 (2002).
   PubMed Web of Science ®Google Scholar
• To KK , RobeyR, ZhanZ, BangioloL, BatesSE. Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway. Mol. Cancer Res.9(4) , 516–527 (2011).
   PubMed Web of Science ®Google Scholar
• Wang Y , WangSY, ZhangXHet al. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem. Biophys. Res. Commun. 356(4) , 998–1003 (2007).
   PubMed Web of Science ®Google Scholar
• Sasakawa Y , NaoeY, NotoTet al. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol. 66(6) , 897–906 (2003).
   PubMed Web of Science ®Google Scholar
• Mie Lee Y , KimSH, KimHSet al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. 300(1) , 241–246 (2003).
   PubMed Web of Science ®Google Scholar
• Kong X , LinZ, LiangD, FathD, SangN, CaroJ. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell. Biol.26(6) , 2019–2028 (2006).
   PubMed Web of Science ®Google Scholar
• Levine B , KroemerG. Autophagy in the pathogenesis of disease. Cell132(1) , 27–42 (2008).
   PubMed Web of Science ®Google Scholar
• Oh M , ChoiIK, KwonHJ. Inhibition of histone deacetylase1 induces autophagy. Biochem. Biophys. Res. Commun.369(4) , 1179–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gonzalez A , LinT, IkedaAK, Simms-WaldripT, FuC, SakamotoKM. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res.68(8) , 2557–2560 (2008).
   PubMed Web of Science ®Google Scholar
• Watanabe M , AdachiS, MatsubaraHet al. Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation. Int. J. Cancer 124(1) , 55–67 (2009).
   PubMed Web of Science ®Google Scholar
• Pei XY , DaiY, GrantS. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res.10(11) , 3839–3852 (2004).
   PubMed Web of Science ®Google Scholar
• Bali P , PranpatM, BradnerJet al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280(29) , 26729–26734 (2005).
   PubMed Web of Science ®Google Scholar
• Nawrocki ST , CarewJS, PinoMSet al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66(7) , 3773–3781 (2006).
   PubMed Web of Science ®Google Scholar
• Newbold A , LindemannRK, CluseLA, WhitecrossKF, DearAE, JohnstoneRW. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol. Cancer Ther.7(5) , 1066–1079 (2008).
   PubMed Web of Science ®Google Scholar
• Fiebig AA , ZhuW, HollerbachC, LeberB, AndrewsDW. Bcl-xL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer6 , 213 (2006).
   PubMed Web of Science ®Google Scholar
• Sasakawa Y , NaoeY, InoueTet al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. 64(7) , 1079–1090 (2002).
   PubMed Web of Science ®Google Scholar
• Roychowdhury S , BaiocchiRA, VourgantiSet al. Selective efficacy of depsipeptide in a xenograft model of Epstein–Barr virus-positive lymphoproliferative disorder. J. Natl Cancer. Inst. 96(19) , 1447–1457 (2004).
   PubMed Web of Science ®Google Scholar
• Paoluzzi L , ScottoL, MarchiE, ZainJ, SeshanVE, O‘ConnorOA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin. Cancer Res.16(2) , 554–565.
   PubMed Web of Science ®Google Scholar
• Byrd JC , ShinnC, RaviRet al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94(4) , 1401–1408 (1999).
   PubMed Web of Science ®Google Scholar
• Klisovic DD , KatzSE, EffronDet al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest. Ophthalmol. Vis. Sci. 44(6) , 2390–2398 (2003).
   PubMed Web of Science ®Google Scholar
• Sawa H , MurakamiH, KumagaiMet al. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol. (Berl.) 107(6) , 523–531 (2004).
   PubMed Web of Science ®Google Scholar
• Marshall JL , RizviN, KauhJet al. A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2(6) , 325–332 (2002).
   PubMedGoogle Scholar
• Byrd JC , MarcucciG, ParthunMRet al. A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105(3) , 959–967 (2005).
   PubMed Web of Science ®Google Scholar
• Piekarz RL , FryeR, TurnerMet al. Completion of the first cohort of patients with cutaneous T-cell lymphoma enrolled on a Phase II trial of depsipeptide. ASH Annual Meeting Abstracts 106(11) , 231 (2005).
   Google Scholar
• Niesvizky R , ElyS, DilibertoMet al. Multicenter Phase II trial of the histone deacetylase inhibitor depsipeptide (FK228) for the treatment of relapsed or refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 106(11) , 2574 (2005).
   Google Scholar
• Whitehead RP , MccoyS, WollnerISet al. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study. J. Clin. Oncol. (Meeting Abstracts) 24(Suppl. 18) , 3598 (2006).
   Web of Science ®Google Scholar
• Su YB , TuttleRM, FuryMet al. A Phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: preliminary toxicity and efficacy experience. J. Clin. Oncol. (Meeting Abstracts) 24(Suppl. 18) , 5554 (2006).
   Web of Science ®Google Scholar
• Molife R , PattersonS, RiggsCet al. Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC). J. Clin. Oncol. (Meeting Abstracts) 24(Suppl. 18) , 14554 (2006).
   Google Scholar
• Whittaker S , McCullochW, RobakT, BaranE, Prentice A; All Investigators. International multicenter Phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): interim report. J. Clin. Oncol. (Meeting Abstracts)24(Suppl. 18) , 3063 (2006).
   Google Scholar
• Piekarz RL , FryeAR, WrightJJet al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin. Cancer Res. 12(12) , 3762–3773 (2006).
   PubMed Web of Science ®Google Scholar
• Cabell C , BatesS, PiekarzRet al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. ASH Annual Meeting Abstracts 114(22) , 3709 (2009).
   Google Scholar
• Morgan M , MaloneyD, DuvicM. Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series. Leuk. Lymphoma43(6) , 1297–1302 (2002).
   PubMed Web of Science ®Google Scholar
• Piekarz RL , RobeyR, SandorVet al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98(9) , 2865–2868 (2001).
   PubMed Web of Science ®Google Scholar
• Bates SE , ZhanZ, SteadmanKet al. Laboratory correlates for a Phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br. J. Haematol. 148(2) , 256–267 (2010).
   PubMed Web of Science ®Google Scholar
• Nebozhyn M , LobodaA, KariLet al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 107(8) , 3189–3196 (2006).
   PubMed Web of Science ®Google Scholar
• Piekarz R , FryeR, WrightJet al. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. J. Clin. Oncol. (Meeting Abstracts) 25(Suppl. 18) , 8027 (2007).
   Web of Science ®Google Scholar
• Piekarz RL , FryeR, PrinceHMet al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117(22) , 5827–5834 (2011).
   PubMed Web of Science ®Google Scholar
• Coiffier B , ProB, PrinceHMet al. Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30(6) , 631–636 (2012).
   PubMed Web of Science ®Google Scholar
• Paoluzzi L , ScottoL, MarchiE, ZainJ, SeshanVE, O‘ConnorOA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin. Cancer Res.16(2) , 554–565 (2010).
   PubMed Web of Science ®Google Scholar
• Dupuis J , CasasnovasRO, MorschhauserFet al. Early results of a Phase Ib/II dose-escalation trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphomas (PTCL). ASH Annual Meeting Abstracts 118(21) , 2673 (2011).
   Google Scholar
• Shimizu R , KikuchiJ, WadaT, OzawaK, KanoY, FurukawaY. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia24(10) , 1760–1768 (2010).
   PubMed Web of Science ®Google Scholar
• Niesvizky R , ElyS, MarkTet al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117(2) , 336–342 (2011).
   PubMed Web of Science ®Google Scholar
• Yu C , RahmaniM, ConradD, SublerM, DentP, GrantS. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood102(10) , 3765–3774 (2003).
   PubMed Web of Science ®Google Scholar
• Catley L , WeisbergE, KiziltepeTet al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108(10) , 3441–3449 (2006).
   PubMed Web of Science ®Google Scholar
• Sutheesophon K , KobayashiY, TakatokuMAet al. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol. 115(1–2) , 78–90 (2006).
   PubMed Web of Science ®Google Scholar
• Berenson JR , YellinO, MapesRet al. A Phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. J. Clin. Oncol. (Meeting Abstracts) 27(15S) , e19508 (2009).
   Web of Science ®Google Scholar
• Klimek VM , FircanisS, MaslakPet al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 14(3) , 826–832 (2008).
   PubMed Web of Science ®Google Scholar
• Odenike OM , AlkanS, SherDet al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin. Cancer Res. 14(21) , 7095–7101 (2008).
   PubMed Web of Science ®Google Scholar
• Schrump DS , FischetteMR, NguyenDMet al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin. Cancer Res. 14(1) , 188–198 (2008).
   PubMed Web of Science ®Google Scholar
• Stadler WM , MargolinK, FerberS, McCullochW, ThompsonJA. A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer5(1) , 57–60 (2006).
   PubMed Web of Science ®Google Scholar
• Whitehead RP , RankinC, HoffPMet al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest. New Drugs 27(5) , 469–475 (2009).
   PubMed Web of Science ®Google Scholar
• Molife LR , AttardG, FongPCet al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 21(1) , 109–113 (2010).
   PubMed Web of Science ®Google Scholar
• Doss HH , JonesSF, InfanteJRet al. A Phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J. Clin. Oncol. 26(Suppl.), Abstract 2567 (2008).
   Web of Science ®Google Scholar
• Luchenko VL , SalcidoCD, ZhangYet al. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 10(18) , 3119–3128 (2011).
   PubMed Web of Science ®Google Scholar

▪ Website

• Bortezomib and Romidepsin in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT00963274). http://clinicaltrials.gov/ct2/show/NCT00963274
   Google Scholar